{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:50:11Z","timestamp":1794851411614,"version":"4.9.1"},"reference-count":28,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:p>Objective. To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD).<\/jats:p>\n               <jats:p>Methods. In this 8-week, randomized, double-blind, placebo-controlled trial, risperidone\/placebo solution (0.01\u20130.06 mg\/kg\/day) was administered to 79 children who were aged 5 to 12 years and had PDD. Behavioral symptoms were assessed using the Aberrant Behavior Checklist (ABC), Nisonger Child Behavior Rating Form, and Clinical Global Impression-Change. Safety assessments included vital signs, electrocardiogram, extrapyramidal symptoms, adverse events, and laboratory tests.<\/jats:p>\n               <jats:p>Results. Subjects who were taking risperidone (mean dosage: 0.04 mg\/kg\/day; 1.17 mg\/day) experienced a significantly greater mean decrease on the irritability subscale of the ABC (primary endpoint) compared with those who were taking placebo. By study endpoint, risperidone-treated subjects exhibited a 64% improvement over baseline in the irritability score almost double that of placebo-treated subjects (31%). Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the ABC; on the conduct problem, insecure\/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom. More risperidone-treated subjects (87%) showed global improvement in their condition compared with the placebo group (40%). Somnolence, the most frequently reported adverse event, was noted in 72.5% versus 7.7% of subjects (risperidone vs placebo) and seemed manageable with dose\/dose-schedule modification. Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure. Extrapyramidal symptoms scores were comparable between groups.<\/jats:p>\n               <jats:p>Conclusions. Risperidone was well tolerated and efficacious in treating behavioral symptoms associated with PDD in children.<\/jats:p>","DOI":"10.1542\/peds.2003-0264-f","type":"journal-article","created":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T00:24:51Z","timestamp":1098145491000},"page":"e634-e641","source":"Crossref","is-referenced-by-count":461,"title":["Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders"],"prefix":"10.1542","volume":"114","author":[{"given":"Sarah","family":"Shea","sequence":"first","affiliation":[{"name":"IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla","family":"Turgay","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Carroll","sequence":"additional","affiliation":[{"name":"Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Schulz","sequence":"additional","affiliation":[{"name":"SciAn Clinical, Etobicoke, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Orlik","sequence":"additional","affiliation":[{"name":"IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Smith","sequence":"additional","affiliation":[{"name":"IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Dunbar","sequence":"additional","affiliation":[{"name":"Janssen-Ortho Inc, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,11,1]]},"reference":[{"key":"2021120819350981000_R1","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Press; 1994"},{"key":"2021120819350981000_R2","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA.\u20082001;285:3093\u20133099","DOI":"10.1001\/jama.285.24.3093"},{"key":"2021120819350981000_R3","unstructured":"Campbell M, Shay J. Pervasive developmental disorders. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry\/IV. Baltimore, MD: Williams & Wilkins; 1995:2277\u20132293"},{"key":"2021120819350981000_R4","unstructured":"Volkmar FR. Autism and the pervasive developmental disorders. In: Lewis M, ed. Child and Adolescent Psychiatry: A Comprehensive Textbook. Baltimore, MD: Williams & Wilkins; 1996:489\u2013502"},{"key":"2021120819350981000_R5","doi-asserted-by":"crossref","unstructured":"Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry.\u20082000;8:45\u201363","DOI":"10.1080\/hrp_8.2.45"},{"key":"2021120819350981000_R6","unstructured":"Janssen PAJ, Niemegeers CJE, Awouters FHL, Schellekens AA, Megens AHP, Meert TP. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-5-HT2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther.\u20081988;244:685\u2013693"},{"key":"2021120819350981000_R7","unstructured":"Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther.\u20081988;247:661\u2013670"},{"key":"2021120819350981000_R8","unstructured":"Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry.\u20081994;55:29\u201335"},{"key":"2021120819350981000_R9","doi-asserted-by":"crossref","unstructured":"Casaer P, Walleghem D, Vandenbussche I, Huang ML, De Smedt G. Pharmacokinetics and safety of risperidone in autistic children. Pediatr Neurol.\u20081994;11:89","DOI":"10.1016\/0887-8994(94)90174-0"},{"key":"2021120819350981000_R10","doi-asserted-by":"crossref","unstructured":"Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol.\u20081996;6:177\u2013190","DOI":"10.1089\/cap.1996.6.177"},{"key":"2021120819350981000_R11","unstructured":"Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull.\u20081997;33:155\u2013159"},{"key":"2021120819350981000_R12","doi-asserted-by":"crossref","unstructured":"Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol.\u20081997;7:167\u2013179","DOI":"10.1089\/cap.1997.7.167"},{"key":"2021120819350981000_R13","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry.\u20081997;36:685\u2013693","DOI":"10.1097\/00004583-199705000-00020"},{"key":"2021120819350981000_R14","doi-asserted-by":"crossref","unstructured":"Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry.\u20081998;37:372\u2013376","DOI":"10.1097\/00004583-199804000-00014"},{"key":"2021120819350981000_R15","doi-asserted-by":"crossref","unstructured":"Zuddas A, Di Martino A, Muglia P, Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol.\u20082000;10:79\u201390","DOI":"10.1089\/cap.2000.10.79"},{"key":"2021120819350981000_R16","doi-asserted-by":"crossref","unstructured":"Masi G, Cosenza A, Mucci M, De Vito G. Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol.\u20082001;16:395\u2013400","DOI":"10.1177\/088307380101600602"},{"key":"2021120819350981000_R17","doi-asserted-by":"crossref","unstructured":"Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry.\u20082001;40:1206\u20131214","DOI":"10.1097\/00004583-200110000-00015"},{"key":"2021120819350981000_R18","doi-asserted-by":"crossref","unstructured":"Malone RR, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry.\u20082002;41:140\u2013147","DOI":"10.1097\/00004583-200202000-00007"},{"key":"2021120819350981000_R19","doi-asserted-by":"crossref","unstructured":"Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord.\u20081980;10:91\u2013103","DOI":"10.1007\/BF02408436"},{"key":"2021120819350981000_R20","unstructured":"Schopler E, Reichler RJ, Renner BR. The Childhood Autism Rating Scale (CARS) for Diagnostic Screening and Classification of Autism. New York, NY: Irvington Publishers; 1986"},{"key":"2021120819350981000_R21","doi-asserted-by":"crossref","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic.\u20081985;89:485\u2013491","DOI":"10.1037\/t10453-000"},{"key":"2021120819350981000_R22","doi-asserted-by":"crossref","unstructured":"Tasse\u0301 MJ, Aman MG, Hammer D, Rojahn J. The Nisonger Behavior Rating Form: age and gender effect and norms. Res Dev Disabil.\u20081996;17:59\u201375","DOI":"10.1016\/0891-4222(95)00037-2"},{"key":"2021120819350981000_R23","unstructured":"Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can J Neurol Sci.\u20081980;7:233"},{"key":"2021120819350981000_R24","doi-asserted-by":"crossref","unstructured":"Aman MG, Singh NN. Aberrant Behavior Checklist Manual. East Aurora, NY: Slosson Educational Publications; 1986","DOI":"10.1037\/t10453-000"},{"key":"2021120819350981000_R25","unstructured":"McDougle CJ, Scahill L, McCracken JT, et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Psychopharmacology.\u20082000;9:201\u2013224"},{"key":"2021120819350981000_R26","doi-asserted-by":"crossref","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med.\u20082002;347:314\u2013321","DOI":"10.1056\/NEJM200212053472316"},{"key":"2021120819350981000_R27","doi-asserted-by":"crossref","unstructured":"Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics.\u20082002;110(3). Available at: www.pediatrics.org\/cgi\/content\/full\/110\/3\/e34","DOI":"10.1542\/peds.110.3.e34"},{"key":"2021120819350981000_R28","unstructured":"Janssen-Ortho Inc. PrRisperidal [product monograph]. Available at: www.janssen-ortho.com\/JOI\/pdf_files\/Risperdal_E.pdf. Accessed July 12, 2004"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/5\/e634\/1019471\/zpe0110400e634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/5\/e634\/1019471\/zpe0110400e634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T21:42:58Z","timestamp":1638999778000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/5\/e634\/67748\/Risperidone-in-the-Treatment-of-Disruptive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,11,1]]},"published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2003-0264-f","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,1]]}}}